Tumore e IA: Insilico Medicine presenterà i primi dati sull’uomo dell’inibitore pan-TEAD ISM6331 a #ESMO26

Insilico Medicine, azienda di ricerca di farmaci basata sull'intelligenza artificiale generativa (IA) in fase clinica, ha ricordato oggi alla comunità oncologica che i dati iniziali della…

AXS Studio will be at #ESMO26 in Madrid this year! Come by booth 8075 to test your sci-viz knowledge and learn how AXS Studio’s expertise can help elevate your science story with stunning, data-backed visual solutions.

#oncology #cancerresearch #biotech #scicomm #biopharm #medtech

Biomarkers, ctDNA and liquid biopsy are reshaping patient selection and oncology trial design. Meet ICON experts at #ESMO26, booth #8005, to discuss the clinical and operational implications for your program. Arrange a meeting: https://ow.ly/pnPg50ZTnME

The #ESMOAmbassadors represent expertise across tumour types and oncology disciplines.
Explore their profiles and discover which Ambassadors to follow during #ESMO26.
🔗 https://ow.ly/cyUC50ZOEjF

𝙏𝙝𝙚 2026 𝙀𝙎𝙈𝙊 𝙇𝘽𝘼 𝙇𝙖𝙣𝙙𝙨𝙘𝙖𝙥𝙚: 𝙑𝙞𝙨𝙪𝙖𝙡𝙞𝙯𝙚𝙙.
Which mechanisms are commanding the late-breaker spotlight this year?

#ESMO2026 #ESMO26 #Oncology #NSCLC #SCLC #ADCs #vaccines #ClinicalData #DrugTrials #CompetitiveStrategy

CARTITUDE-2試験の5年データ：単回の #Carvykti 投与により、早期再発 #多発性骨髄腫 患者の50%が維持療法なしで無増悪を維持（PFS中央値：60.5カ月）
www.ipharmacenter.com/post/interna...
#IMS2026 #ESMO26 #がん

CARTITUDE-2 五年随访数据：单次 #Carvykti 输注使 50% 早期复发的 #多发性骨髓瘤 患者在无需维持治疗的情况下保持无进展生存（中位 PFS：60.5 个月）
www.ipharmacenter.com/post/interna...
#IMS2026 #ESMO26 #癌症

Dati a 5 anni da CARTITUDE-2: Una singola infusione di #Carvykti ha mantenuto il 50% dei pazienti con #mielomamultiplo in recidiva precoce libero da progressione senza terapia di mantenimento (PFS mediana: 60,5 mesi)
www.ipharmacenter.com/post/interna...
#IMS2026 #ESMO26 #Cancro

With #ESMO26 in Madrid around the corner, the LBAs list os now available online and in the program!

#ESMOAmbassadors

📣 #ESMO26: The late-breaking abstract lineup is taking shape!
Authors & titles are online, and most of the submissions are already there. 30K+ delegates already registered from around the world, so this means new data, new insights and new opportunities to connect.

🔗 https://ow.ly/6Res50ZQ82a

Attending #ESMO2026 in Madrid? So is the ONCrg team!
Our oncology experts will be on the ground, analyzing the latest practice-changing clinical data, trial results, and emerging scientific insights as they unfold across over 20 tumor types.

#ESMO26 #Oncology #LungCancer #nsclc #sclc #ONCrg

I am thrilled to be part of this group with stellar ⭐️ colleagues and I look forward to interactions and discussions around high quality data at #ESMO26 !

#ESMOAmbassadors

ESMO is pleased to announce the #ESMOAmbassadors for #ESMO26.
They will share scientific highlights, expert perspectives and insights on the latest research presented at #ESMO26 across tumour types and disciplines.

🔗Discover the Ambassadors: https://ow.ly/BQ3i50ZOkEv

📣 #ESMO26: 4 Keynotes. 1 stage. The next frontier of oncology – CNS disease, AI-driven prediction, radioligand therapy & the role of ageing in cancer.

⏰ Last chance to register at preferential fees - late registration deadline: 16 September 2026
🔗 https://ow.ly/xh2Y50ZLVMY

#esmomeetings

📣 #ESMO26: Join Prof. James Larkin, Scientific Committee Co-Chair, to exchange perspectives, debate emerging evidence, and discuss the future of cancer prevention, diagnosis, and treatment.

⏰ Late registration deadline: 16 September 2026
🔗 https://ow.ly/q9GM50ZJcZh

#esmomeetings